|
|
Article: Oragenics Initiates Phase I Safety Study of Novel Treatment for Preventing Tooth Decay.
- Article from:
- Business Wire
- Article date:
- May 2, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ALACHUA, Fla. -- Oragenics, Inc. (AMEX:ONI) today announced the start of a Phase I clinical study of its Replacement Therapy, a novel approach to the prevention of tooth decay. The study, being conducted in six couples and an additional nine individuals at Hill Top Research in West Palm Beach, Florida, will look at the safety of Replacement Therapy and the potential for horizontal transmission of the Replacement Therapy organism to the non-treated member of each couple.
"We are very pleased to begin human testing of Replacement Therapy, which our research to date suggests has great potential as a new preventive therapy against tooth decay," said Chuck Soponis, ...